124676-19-3

Basic information

• Product Name: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID
• Synonyms: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID;2-(1H-Benzotriazol-1-yl)-2-[(benzyloxycarbonyl)amino]acetic acid;alpha-[[(Phenylmethoxy)carbonyl]amino]-1H-benzotriazole-1-acetic acid;2-(1H-Benzo[d][1,2,3]triazol-1-yl)-2-(benzyloxycarbonylamino)acetic acid;α-[[(PhenylMethoxy)carbonyl]aMino]-1H-benzotriazole-1-acetic Acid;2-(1H-Benzo[d][1,2,3]triazol-1-yl)
• CAS NO: 124676-19-3
• Molecular Formula: C₁₆H₁₄N₄O₄
• Molecular Weight: 326.31
• Product Categories: pharmacetical
• Mol File: 124676-19-3.mol

Chemical Properties

• Melting Point: 162-164℃
• Boiling Point: 596.4°C at 760 mmHg
• Flash Point: 314.5°C
• Appearance: /
• Density: 1.43
• Vapor Pressure: 4.51E-15mmHg at 25°C
• Refractive Index: 1.675
• Storage Temp.: 2-8°C
• PKA: 2.55±0.10(Predicted)
• CAS DataBase Reference: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID(124676-19-3)
• EPA Substance Registry System: BENZOTRIAZOL-1-YL-BENZYLOXYCARBONYLAMINO-ACETIC ACID(124676-19-3)

Safety Data

• Hazardous Substances Data: 124676-19-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H14N4O4/c21-15(22)14(20-13-9-5-4-8-12(13)18-19-20)17-16(23)24-10-11-6-2-1-3-7-11/h1-9,14H,10H2,(H,17,23)(H,21,22)

Upstream product

• 95-14-7 1,2,3-Benzotriazole 
• 621-84-1 O-benzyl carbamate 
• 298-12-4 Glyoxilic acid 

Downstream Products

• 280568-18-5 {Benzotriazol-1-yl-[2-(pyridine-3-carbonyl)-phenylcarbamoyl]-methyl}-carbamic acid benzyl ester 
• 682812-78-8 {Benzotriazol-1-yl-[2-(4-trifluoromethyl-benzoyl)-phenylcarbamoyl]-methyl}-carbamic Acid Benzyl Ester 
• 108895-98-3 benzyl 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamate 
• 1206716-08-6 [benzotriazol-1-yl(2-(4-chloro-benzoyl)-phenylcarbamoyl)-methyl]-carbamic acid benzyl ester 
• 1300090-27-0 C₃₀H₂₅N₅O₄ 
• 1300090-04-3 benzyl N-(7-iodo-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamate 
• 1449305-67-2 benzyl N-(7-iodo-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamate 
• 1300090-44-1 phenylmethyl (1-(1H-1,2,3-benzotriazol-1-yl)-2-{[2-[(4-chlorophenyl)carbonyl]-4-(methyloxy)phenyl]amino}-2-oxoethyl)carbamate 
• 1300090-01-0 phenylmethyl (2-oxo-5-phenyl-2,3-dihydro-1H-[1]benzofuro[3,2-e][1,4]diazepin-3-yl)carbamate 
• 1300090-45-2 phenylmethyl (1-(1H-1,2,3-benzotriazol-1-yl)-2-oxo-2-{[2-(phenyl carbonyl)-1-benzofuran-3-yl]amino}ethyl)carbamate 
• 153826-05-2 [1-(2-Hydroxy-ethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 1345046-36-7 C₂₆H₂₅N₃O₄ 
• 1355613-71-6 C₁₉H₁₉N₃O₄ 
• 1345046-74-3 C₁₉H₁₇N₃O₄ 

Relevant articles and documents

COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS

The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.

BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

BENZODIAZEPINE DERIVATIVES AS CCK2/GASTRIN RECEPTOR ANTAGONISTS

The invention relates to benzodiazepine derivatives of formula (A) useful as CCK2/gastrin receptor antagonists, their preparation and their use in the treatment or prevention of disorders associated with CCK2/gastrin receptors, disorders caused by or associated with hypergastrinaemia, and gastric acid-related disorders.

Discovery of clinical candidate BMS-906024: A potent pan-notch inhibitor for the treatment of leukemia and solid tumors

Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated doses in

Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors

As the best-characterized ubiquitin-like protein (UBL), small ubiquitin-related modifier (SUMO) was found to conjugate with a number of proteins to regulate cellular functions including transcription, signal transduction, and cell cycle. While E1, E2 and E3 ligases are responsible for the forward SUMOylation reaction, SUMO-specific proteases (SENPs) reversibly removeSUMOfrom the SUMOylated proteins. Recently, SENP1 was found to be a potential therapeutic target for the treatment of prostate cancers, but the design and synthesis of its inhibitors have not been reported. We designed and synthesized a series of benzodiazepinebased SENP1 inhibitors, and they showed inhibitory activity as good as IC50 = 9.2 μM (compound 38). The structure-activity relationship was also discussed.

BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION

Use of a benzodiazepine of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing a hepatitis C infection, wherein: - R1 represents C1-6 alkyl, aryl or heteroa

1,4-Benzodiazepines as inhibitors of respiratory syncytial virus

Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as a serious threat to patient groups with poorly functioning immune systems. Our approach to finding a novel inhibitor of this virus was to screen a 20 000-member diverse library in a whole cell XTT assay. Parallel assays were carried out in the absence of virus in order to quantify any associated cell toxicity. This identified 100 compounds with IC50's less than 50 μM. A-33903 (18), a 1,4-benzodiazepine analogue, was chosen as the starting point for lead optimization. This molecule was moderately active and demonstrated good pharmacokinetic properties. The most potent compounds identified from this work were A-58568 (47), A-58569 (44), and A-62066 (46), where modifications to the aromatic substitution enhanced potency, and A-58175 (42), where the amide linker was modified.

BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV. Formula (I) Wherein: - R1 represents C1-6 alkyl, aryl or heteroaryl; - R2 represents hydrogen or C1-6 alkyl; - each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2RI, -CONRIRII, -NH-CO-RI, -S(O)RI, -S(O)2RI, -NH-S(O)2RI, -S(O)NRIRII or -S(O)2NRIRII wherein each RI and RII is the same or different and represents hydrogen or C1-6 alkyl; - n is from 0 to 3; R4 represents hydrogen or C1-6 alkyl; - R6 represents C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or, -XR6; - X represents -CO-, -S(O)- or -S(0)2-; and - R6 represents C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-(C 1-6hydroxyalkyl)-, heteroaryl-(C1-6 hydroxyalkyl)-, carbocyclyl-(C1-6 hydroxyalkyl)-, heterocyclyl-(C 1-6 hydroxyalkyl)-, aryl-(C 1-6alkyl)-O-, heteroaryl-(C 1-6alkyl)-O-, carbocyclyl-(C1-6 alkyl)-O-, heterocyclyl-(C1-6 alkyl)-O- or -NRIRII wherein each RI and RII is the same or different and represents hydrogen, C1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl- (C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)- or heterocyclyl-(C1-6 alkyl)-.

Process of preparing benzodiazepine compounds useful as antagonists of CCK or of gastrine

A benzodiazepine derivative of formula I, or a pharmaceutically acceptable salt thereof: STR1 wherein: (a) R4 is an alkyl, cycloalkyl or aryl group. (b) R10 is chosen from halo, OH, CH3, OCH3, NR11 R12, NO2, NHCHO, CO2 H and CN, and R11 and R12 are independently selected from H and alkyl (C1 -C5) or together NR11 R12 form a cyclic structure II, STR2 wherein a is 1-6; and (c) R2 is an aromatic 5- or 6-membered, substituted or unsubstituted heterocycle containing at least two heteroatoms of which at least one is nitrogen. These compounds are gastrin and/or CCK-B receptor antagonists.